Diabetes is characterized by insulin resistance and a reduction in insulin secretion, leading to progressive b-cell failure and loss of b-cell mass. Its central therapeutic issues are how to restore glucose responsiveness of b-cells to normal and counteract defects in insulin secretion. Native glucagon-like peptide-1 (GLP-1), which makes b-cells competent and diabetic b-cells specifically more sensitive to glucose, has a major drawback of rapid inactivation. In this study, we describe the construction and analysis of a GLP-1 plasmid and double-stranded, adeno-associated viral (dsAAV) expression vector to overcome both the rapid degradation of native GLP-1 and limitations of gene therapy using standard single-stranded AAV. Our study results demonstrate that fasting blood glucose levels of db/db obese mice decreased significantly up to 4 months after a single injection of dsAAV GLP-1, and both insulin and circulating GLP-1 levels increased in dsAAV GLP-1-infected mice. These results demonstrate that dsAAV GLP-1 has long-term, efficient transgene expression with minimal toxicity and cellular immune responses. This study suggests that GLP-1 produced by dsAAV may be an alternative to the continuous infusions required for GLP-1 peptide therapy or daily injections of GLP-1. Gene Therapy (2011) (T2D) is a disorder of glucose homeostasis characterized by hyperglycemia, peripheral insulin resistance, impaired hepatic glucose metabolism and diminished glucose-dependent secretion of insulin from pancreatic b-cells. 1 These pathologies result in progressive b-cell failure, resulting in the loss of b-cell mass. 2, 3 There is consequently a need for either single hypoglycemic agents or agents that can be combined with insulin surrogate therapy to control blood glucose. From a therapeutic viewpoint, an important issue is how to restore the normal responsiveness of b-cells to glucose so that insulin secretion can occur. The incretin hormone, glucagon-like peptide-1 (GLP-1), has attracted much attention as it can counteract uncontrolled insulin secretion. 4 The 'incretin effect' refers to the amplification of insulin secretion elicited by hormones secreted from the gastrointestinal tract. 5 The pro-glucagon-derived peptide GLP-1 is produced by L cells in the small intestine in response to fat and carbohydrates. GLP-1 makes b-cells competent and sensitizes diabetic b-cells specifically to glucose, thereby restoring normal insulin secretion by its insulinotropic actions on b-cells. These glucose-dependent effects include cAMP formation, insulin secretion, insulin biosynthesis and pro-insulin gene expression. 6,7 GLP-1 also enhances b-cell mass by inhibition of b-cell apoptosis and stimulation of b-cell proliferation in the rodents. 8, 9 However, the use and development of GLP-1 as a therapeutic agent in vivo is hampered by its short half-life; this peptide hormone is degraded by dipeptidyl peptidase-4 (DPP-IV, natural inhibitor of GLP-1) and neutral endopeptidase, and is cleared by the kidneys. 10 Because of extensive degradation, plasma concentrations of the intact hormone are very low and may not even rise significantly in response
INTRODUCTION
Type II diabetes (T2D) is a disorder of glucose homeostasis characterized by hyperglycemia, peripheral insulin resistance, impaired hepatic glucose metabolism and diminished glucose-dependent secretion of insulin from pancreatic b-cells. 1 These pathologies result in progressive b-cell failure, resulting in the loss of b-cell mass. 2, 3 There is consequently a need for either single hypoglycemic agents or agents that can be combined with insulin surrogate therapy to control blood glucose. From a therapeutic viewpoint, an important issue is how to restore the normal responsiveness of b-cells to glucose so that insulin secretion can occur. The incretin hormone, glucagon-like peptide-1 (GLP-1), has attracted much attention as it can counteract uncontrolled insulin secretion. 4 The 'incretin effect' refers to the amplification of insulin secretion elicited by hormones secreted from the gastrointestinal tract. 5 The pro-glucagon-derived peptide GLP-1 is produced by L cells in the small intestine in response to fat and carbohydrates. GLP-1 makes b-cells competent and sensitizes diabetic b-cells specifically to glucose, thereby restoring normal insulin secretion by its insulinotropic actions on b-cells. These glucose-dependent effects include cAMP formation, insulin secretion, insulin biosynthesis and pro-insulin gene expression. 6, 7 GLP-1 also enhances b-cell mass by inhibition of b-cell apoptosis and stimulation of b-cell proliferation in the rodents. 8, 9 However, the use and development of GLP-1 as a therapeutic agent in vivo is hampered by its short half-life; this peptide hormone is degraded by dipeptidyl peptidase-4 (DPP-IV, natural inhibitor of GLP-1) and neutral endopeptidase, and is cleared by the kidneys. 10 Because of extensive degradation, plasma concentrations of the intact hormone are very low and may not even rise significantly in response to small meals. Recent studies have shown that inhibition of this enzyme can enhance the half-lives of both endogenous and exogenous GLP-1 in vivo. 11 The adeno-associated virus (AAV) vector has attractive characteristics; it is infectious to nondividing cells and not pathogenic. 12 In addition, the AAV vector, which lacks viral genes, can evade clearance mechanisms that result from the immunity of transduced cells. 13 These advantages allow AAV vectors to be used for efficient and long-term gene transfer in muscle, 14 brain 15 and liver 16 as well as in a variety of other tissues. [17] [18] [19] Recent reports showed that AAV can predominantly package double-stranded, hairpin-like dimer DNA by mutating the inverted terminal repeat (ITR), accelerating transduction both in vitro and in vivo. 20, 21 In this study, we describe the construction and analysis of doublestranded AAV (dsAAV) expression vectors containing a GLP-1 plasmid. The transduction of these agents results in elevated levels of circulating GLP-1 peptide in vitro. Furthermore, we demonstrate the efficacy of these vectors in the treatment of T2D in db/db mice. Our results provide proof that gene therapy using GLP-1 is a safe and long-lasting treatment option for T2D.
RESULTS

Plasmid construction and efficient packaging of dsAAV
The self-complementary AAV vector plasmid generates viral particle harboring double-stranded viral genome in the form of hairpin because of a modified ITR of vector plasmid.
To confirm that our dsAAV vector has a double-stranded genome, we performed electrophoresis with the viral DNA extracted from dsAAV vector under both neutral and alkaline conditions ( Figure 1b ).
DNAs purified from dsAAV GLP-1 (2.1 kb) were observed at 2.1 kb on the neutral gel compared with dsDNA marker that was detected at 4.2 kb denatured into a linear single-stranded DNA on the alkaline gel. These results show that double-stranded viral genome like hairpin was denatured into a linear ssDNA of 4.2 kb. Single-stranded viral genome from the conventional AAV DNA (AAV LacZ, 4.7 kb), however, located at 3 kb on the neutral gel and migrated at 4.7 kb, which is the same size of the original single-stranded AAV (ssAAV) DNA, on the alkaline gel. These results confirmed that the dsAAV vector was efficiently packaged as a double-stranded genome.
Improvements in gene delivery and GLP-1 expression efficiency of dsAAV Expression plasmids containing a series of different sequences upstream of the active GLP-1 gene were transfected into 293T cells, and the cell supernatants were assayed for the presence of GLP-1 2 days after transfection. Radioimmunoassays (RIAs) specific for the N and C termini of GLP-1 confirmed the presence of significant amounts of processed GLP-1 in the cell supernatants (Figure 2a ). Data from a representative experiment using the C-terminal RIA were shown in Figure 2a . The construct, containing a furin-cleavable leader sequence between the hemagglutinin A (HA) tag and the GLP-1 gene, produced more GLP-1 than did constructs containing just a signal peptide or a furin-cleavable sequence downstream of the leader sequence. No active, secreted GLP-1 was detected using the N-terminal-specific RIA except from the construct containing the signal peptide, HA epitope and furin-cleavable site (Figure 2a, right) .
We compared the transduction efficiencies of the dsAAV and ssAAV vectors in 293T cells. On day 2 after infection, the culture medium was collected and assayed for GLP-1 using a GLP-1 enzyme-linked immunosorbent assay (ELISA) kit (Linco, St Charles, MO, USA).
Transduction of cells with the dsAAV GLP-1 vector yielded 2.8-fold more secreted GLP-1 after infection than did transduction with the same dose (5000 viral genome (v.g.) per cell) of ssAAV (Figure 2b, left) .
We also measured secreted GLP-1 using a C-terminal-specific GLP-1 RIA assay kit to determine whether the expression of this peptide was dependent on the dose of vector with which the cells were transfected. Infection of cells with the dsAAV GFP control vector at a dose of 10 000 v.g. per cell yielded no detectable secreted GLP-1, whereas infection at a dose of 1000 v.g. per cell yielded significantly higher concentrations of secreted GLP-1. Furthermore, the cells transduced with dsAAV GLP-1 expressed GLP-1 in a dose-dependent manner (Figure 2b , right). We could also detect intracellular GLP-1 using immunocytochemistry (Figure 2c , left) and secreted GLP-1 by immunoprecipitation (Figure 2d ) expressed from dsAAV GLP-1-infected cells.
Biological activity of GLP-1 secreted by dsAAV GLP-1 To determine whether the expressed GLP-1 peptides were biologically active, we treated INS-1 cells with media from 293T cells infected with the dsAAV vector. We used a luciferase-based reporter, pCRE-Luc, which contains cAMP response elements in the promoter region. Therefore, this plasmid can be used to detect cAMP upregulation. INS-1E cells were transiently transfected with pCRE-Luc. After 4 h, the culture medium was replaced with fresh medium containing the transduction medium of 293T cells. Treatment of cells with conditioned medium obtained from dsAAV GLP-1-infected cells resulted in a significant increase in CRE-Luc activity compared with that of dsAAV GFP-transduced cells (Figure 3a) . These results suggest that GLP-1 expressed in virally transduced 293T cells is processed normally and that the secreted GLP-1 is biologically active even in the presence of DPP-IV in the culture medium.
Native GLP-1 stimulates insulin secretion from b-cells in a glucosedependent manner. To further evaluate whether the GLP-1 secreted from mammalian cells is functional, we determined its effect on insulin secretion from insulin-secreting INS-1E cells. As shown in Figure 3b , control viral vector-infected cells responded to glucose stimulation with a 1.6-fold increase in insulin secretion. Under similar conditions, dsAAV GLP-1 vector-infected cells responded to glucose stimulation with a 3.07-fold increase in insulin secretion (Figure 3b) , despite a viral transduction efficiency of less than 50% (data not shown).
Long-term effects of dsAAV GLP-1 vector transduction in vivo Diabetic db/db mice (7-to 8-week old) were used to characterize the effects of dsAAV GLP-1 in vivo. Blood glucose levels were evaluated every week after injection of viral vectors. The fasting blood glucose levels of dsAAV GLP-1-treated mice were significantly lower than control mice, and this effect lasted for approximately 4 months (Figure 4a ). In addition, a glucose tolerance test performed at 12 weeks after administration of vector showed that dsAAV GLP-1-treated db/db mice had improved glucose homeostasis (Figure 4b ). Although blood glucose excursion was similar between the two groups, the GLP-1-treated animals showed rapid serum clearance of glucose at the 90-and 120-min time points (Figure 4b) .
We investigated whether the maintenance of circulating insulin levels was reflected in the preservation of b-cell mass. At 14 weeks after vector administration, pancreatic sections were immunostained for insulin. Lean C57BL/6 J mice showed small, densely staining islets, whereas db/db mice had larger, lightly staining islets. The dsAAV GLP-1-treated db/db mice tended to have larger islets than did the control db/db mice (Figure 4c ). This analysis demonstrated a 1.4-fold increase in b-cell mass in dsAAV GLP-1-treated mice compared with dsAAV GFP-treated mice.
Prolonged GLP-1 expression and increased insulin levels in dsAAV GLP-1-infected mice Plasma GLP-1 levels were more elevated in mice injected with dsAAV GLP-1 than the control (Figure 5a ) at 2 weeks after viral injection, Considering that the fasting blood glucose levels of the dsAAV GLP-1-treated group were lower than control mice, GLP-1 is likely expressed from dsAAV GLP-1 in treated db/db mice after 1 week, even though blood levels of GLP-1 were not measured. Fasting blood glucose levels rose again 4 months after injection, correlating with low levels of GLP-1 in the bloodstream (Figure 5a ). Furthermore, nonfasting insulin levels were significantly higher in the dsAAV GLP-1-injected mice than in the control mice (3.67 vs 8.76 ng ml À1 ) (Figure 5b ).
To determine the influence of dsAAV GLP-1 on the size of the area containing insulin-positive cells, we performed double immunological staining of pancreatic sections. GLP-1 viral vector treatment resulted in an increase in the size of insulin-positive areas ( Figure 5c ). Quantitative morphological analysis suggested that the insulinpositive areas in individual islets were significantly increased by dsAAV GLP-1 treatment more than 2.5-fold to control, whereas dsAAV GFP-treated islets only had a few insulin-producing b-cells and spatial derangement of the islet endocrine cells (Figure 5c ).
Increased gene expression in the liver and pancreas of dsAAV vector-treated mice
To confirm whether the elevated expression of GLP-1 was due to production of exogenous GLP-1, we measured GLP-1 mRNA levels in the livers of infected mice using reverse transcription (RT)-PCR with gene-specific primers. GLP-1 transcripts were detected in only dsAAV GLP-1-treated db/db mice, whereas GFP transcripts were detected only in only dsAAV GFP-treated db/db mice. No transcripts were detected in the total RNA extracted from liver tissues without reverse transcription ( Figure 6a ). These data show that RNA levels correlate well with plasma GLP-1 levels as shown in Figure 5a . We also detected a significant increase in insulin mRNA transcripts in dsAAV GLP-1-treated mice (Figure 6b ). In other words, GLP-1 transduction stimulated insulin biosynthesis and increased insulin exocytosis.
Diabetes is associated with the development of endoplasmic reticulum stress in b-cells. The transcription factor CHOP has been shown to be a critical component of the endoplasmic reticulum stress response. We found significantly lower levels of CHOP mRNA in dsAAV GLP-1-treated pancreas tissue than in dsAAV GFP-treated pancreas tissue (Figure 6b ). DISCUSSION GLP-1 derived from intestinal endocrine L cells functions as an incretin: it augments nutrient-stimulated insulin release from islet b-cells in the postprandial state. 22, 23 GLP-1 thus exerts a potent antidiabetic effect by binding to the GLP-1 receptor. Although these properties of GLP-1 have stimulated interest in using GLP-1 to treat T2D, native GLP-1 has a very short half-life. Daily administration is therefore required to normalize blood glucose levels. To extend the half-life of GLP-1, one group tested analogs of a GLP-1R agonist; these compounds were found to have potent blood glucose-lowering effects, but the effects were peptidase resistant. 24 Exendin-4 (EX4) has a high affinity for the GLP-1 receptor [25] [26] [27] and is a poor substrate for DPP-IV and neutral endopeptidase, resulting in a greatly extended half-life. NN2211 (liraglutide), which is another stable GLP-1 derivative, is protected from degradation from DPP-IV by binding to serum albumin. 28 A gene therapy approach has been shown to lower blood glucose levels effectively in a murine model of severe T2D, with a longlasting therapeutic effect. Although both plasmid-based and adenoviral systems have been used to express GLP-1R agonists recently, [29] [30] [31] [32] these systems yield relatively short-term expression. AAV has been considered another attractive vector. AAV vectors are derived from the AAV type 2 virus, a nonpathogenic, replication-defective parvovirus, 13, 33, 34 that can integrate into the host genome at a specific locus. AAV vectors are able to effectively transduce both dividing and non-dividing cells in vitro and in vivo, allowing stable gene transfer by either integration into the host chromosomes or persistence as an episome. 35, 36 In addition, the lack of cytotoxicity and minimal cellular immune responses after AAV-mediated in vivo gene transfer also contribute to the success of long-term gene delivery using this vector in a variety of tissues. 37 Unlike other DNA-based viral and nonviral vectors, such as adenoviral vectors and plasmids, AAVs package and deliver a singlestranded DNA genome that is transcriptionally inactive until it is converted into a double-stranded template. The rate-limiting steps for the conversion of ssDNA to dsDNA are the de novo synthesis of the second strand of DNA and the annealing of the plus and minus strands from two separate viral particles co-infecting the same cell. 38, 39 Therefore, there is an extended lag period before transgene expression actually occurs although AAV is a safe vector for gene therapy. McCarty et al. 40 used a double-stranded form of the AAV singlestranded genome to reduce the lag period for transgene expression. Wang et al. 20 discovered that if the D-sequence with the terminal resolution site is deleted from one of the ITRs, cleavage by Rep cannot occur and, consequently, the dimers are not resolved into monomers, allowing the double-stranded genomes to be packaged as large hairpin DNA molecules. Therefore, a gene therapy approach using dsAAV vector exerting long-lasting effects supposed to have several advantages over parental protein drug delivery. In this article, we present a new strategy to produce dsAAV vectors efficiently and show accelerated and robust transgene expression from these vectors both in vitro and in an in vivo animal model, namely diabetic db/db mice. Our results showed that the dsAAV vector could effectively transduce cells, and higher concentrations of GLP-1 were detected in the culture medium of cells transfected with this vector, corresponding to the recent report that GLP-1 gene therapy using dsAAV (type 8) viral vector mitigated the onset of diabetes in STZ-induced mice. 41 In this study, we first constructed several GLP-1 expression vectors encoding secretable and active GLP-1 (7-37) mutated alanine to glycine at position 8. It makes the GLP-1 to render DPP-IV-resistant and to extend its circulating half-life. 42 The plasmid that contained a leader sequence, an intervening HA tag and a furin-recognition site upstream of the GLP-1 gene produced the greatest amount of GLP-1 and, interestingly, produced more GLP-1 than did a plasmid with a furin site but without an HA tag. Furin is a type of protein convertase that is involved in the conversion of pro-hormones and precursor proteins into biologically active peptides and proteins. 43 Although it is expressed ubiquitously, it is predominantly a Golgi membranelocalized endoprotease that efficiently processes precursor proteins at paired basic residues (-Lys-Arg-or -Arg-Arg-) in transfected cells. 44 Furin has recently been shown to show P6 recognition at the cleavage site, and basic residues at P6 result in enhanced substrate cleavage. 45 Our GLP-1 expression cassette had an HA sequence upstream of GLP-1. The basic amino-acid residues in the terminus of the HA peptide are likely to be involved in furin specificity, thereby contributing to efficient processing. Cells transfected with dsAAV-GLP-1 produced higher levels of circulating GLP-1 (7-37) than endogenous GLP-1 levels. cAMP and insulin secretion assays demonstrated that the secreted protein was able to activate GLP-1Rs in INS-1 cells. Furthermore, GLP-1 stimulated insulin secretion in a glucose-dependent manner, indicating that the GLP-1 protein was biologically active. Our results are consistent with the characterized function of GLP-1: making b-cells more insulin sensitive to glucose. 1 Circulating GLP-1 proteins were detectable in db/db mice 2 weeks after intravenous injection of dsAAV GLP-1, but not after injection with control virus. The db/db mice are a rodent model for T2D; they genetically lack the leptin receptor and have a severe form of progressive diabetes characterized by loss of b-cells. 46 Pharmacological levels of GLP-1R agonists are known to promote weight loss, which is attributed to delayed gastric emptying and satiety, Effect of dsAAV GLP-1 on blood GLP-1 levels, insulin levels and b-cell staining in db/db mice. (a) Plasma was collected before injection and 2, 14, 18 and 28 weeks after injection. GLP-1 levels were determined using a C-terminal-specific GLP-1 RIA kit. (b) Blood insulin levels were measured using ELISA at 14 weeks after a 15 h fast. (c) Mouse pancreata collected 14 weeks after viral transduction were immunostained with anti-insulin and antiglucagon antibodies and visualized using FITC-and rhodamine-conjugated second antibodies, respectively (left). Morphometric analyses of 30 islets per pancreas from 3-4 mice for each group were carried out to measure the size of the insulin-positive areas (right). The positive area in a dsAAV GFP-transduced db/db mouse is shown by the open column, whereas that for a dsAAV GLP-1-transduced db/db mouse is shown by the gray column. Each column represents a mean ± s.d. Bar¼100 mm. *Po0.01, **Po0.001.
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and have direct effects on central nervous system appetite centers. 47 However, we cannot see any effect of dsAAV GLP-1 on body weight, which has been seen in some cases after native GLP-1 treatment in rodent models. 29, 48 With a single injection of dsAAV GLP-1, we achieved circulating GLP-1 levels approximately 4-to 10-fold higher than endogenous levels of GLP-1, and this expression was sustained for 18 weeks. GLP-1 stimulates intracellular cAMP production and elevates (Ca 2+ ) I in a glucose-dependent manner, leading to activation of downstream signaling pathways involved in cell proliferation, survival, acute insulin secretion, insulin synthesis and preservation of b-cell function. 49 Consistent with these findings, our in vivo results demonstrated increased insulin release in response to glucose challenge in db/db obese mice treated with dsAAV GLP-1. dsAAV GLP-1 enhanced the ability of the pancreas to release insulin and significantly increased b-cell mass. The reduced fasting blood glucose levels in dsAAV GLP-1-infected mice were associated with increased insulin and circulating GLP-1 levels. This improvement was therefore attributed to enhanced insulin secretion and pancreatic insulin content. These findings suggest that functional b-cell mass is important for controlling glycemia in obese db/db mice. Recent studies have revealed that apoptosis in b-cells is induced by endoplasmic reticulum. 37, 50 Our results demonstrate dsAAV GLP-1 treatment not only ameliorated hyperglycemia through both insulin secretion and insulin biosynthesis but also significantly reduced biochemical markers of islet endoplasmic reticulum stress in vivo. Our study shows results to ameliorate T2D for long term by dsAAV type 2.
In this study, our study goal was to demonstrate that secreted DPP-IV-resistant GLP-1 produced from dsAAV GLP-1 can be used to treat T2D in vivo. Our results clearly demonstrate that dsAAV GLP-1 is effective at treating diabetes in a rodent model of severe diabetes and that this effect is long lasting. Taken together, treatment with dsAAV GLP-1 is an alternative to either continuous infusion of GLP-1 or to daily injection of stabilized forms of GLP-1 or EX4.
MATERIALS AND METHODS
Plasmid construction
The self-complementary AAV vector plasmid that generates double-stranded viral DNA was constructed by deleting the D sequence of the 5¢ ITR with MscI digestion as described previously. 20 MscI removed the D sequence and the terminal resolution site (nucleotides 122-144 of AAV2 genome). The ITR on the 3¢ terminus of the vector remained intact (wild type). For expression vector construction, the CB promoter (CMV enhancer/chicken b-actin promoter) was used for stable liver gene expression. For efficient GLP-1 secretion, we constructed a plasmid encoding a fusion protein consisting of the Murine Ig k-chain leader sequence to target the peptide to the constitutive secretory pathway, and we inserted an HA epitope tag between the leader sequence and the GLP-1-coding region. To obtain expression of biologically active GLP-1, we also inserted a furin protease recognition sequence immediately upstream of a GLP-1 (7-37) gene (Figure 1a) .
To generate dsAAV vectors that predominantly package double-stranded hairpin-like dimer DNA, we deleted the D sequence and the terminal resolution site of the left ITR on the AAV vector while keeping the right ITR intact. We produced both the conventional AAV and dsAAV vectors based on AAV serotype 2.
Production of AAV vector
To generate dsAAV particles, we transfected 293T cells by calcium phosphate with plasmid DNA (pRC, pAdDF6 and the dsAAV2 cis vector) and collected cells 3 days after transfection. The cell pellet was resuspended in 20 mM Tris (pH 8.0)-150 mM NaCl. Deoxycholate was added to a final concentration of 0.5% and benzonase (50 U ml À1 ; American International Chemical, Natick, MA, USA) was concurrently added and incubated for 30-40 min at 37 1C. Cellular debris was then removed by centrifugation at 3000 g for 15 min at 4 1C. The clarified lysate was frozen in a dry ice/ethanol bath. After thawing the supernatant, any flocculent precipitate was removed by centrifugation, and the supernatant was filtered through a 0.45 mm pore-sized syringe filter to remove any particulate matter before heparin column purification. The cleared crude lysate was then applied on a heparin column (GE Healthcare Biosciences, Niskayuna, NY, USA) by using a P1 pump pre-equilibrated with 20 mM Tris (pH 8)-150 mM NaCl. After all the lysate went through the column, the column was washed with 20 mM Tris-100 mM NaCl. The virus was then eluted by application of a linear NaCl gradient from 0.2 to 0.5 M. To concentrate the viral stock and to adjust the NaCl concentration to physiological level, we concentrated the elute using Amicon Ultra centrifugal filter device. AAV stocks were stored at À80 1C.
To Characterize dsAAV viral DNA, we extracted the viral DNA from a sample of purified viral vector by treating it with digestion buffer (50 mM Tris-Cl (pH 8.0), 1 mM EDTA (pH 8.0), 1% sodium sarkosyl sulfate, 1.0 mg of proteinase K per ml) at 50 1C for 1 h. Agarose gel electrophoresis analysis (0.8%) of viral DNA was performed as previously described. Briefly, for the neutral agarose electrophoresis the viral DNA dissolved in TE buffer (pH 7.6) was boiled for 5 min and immediately cooled on ice except the DNA marker. For the alkaline agarose gel electrophoresis, the viral DNA and the marker were dissolved in alkaline gel loading buffer. 
Quantification of recombinant AAV particles
Viral genome copies were determined by real-time PCR for purified recombinant AAV viral stocks DNase-resistant particle quantification. 51 The virus stock was prepared to 10 4 dilution in PCR buffer. The samples were digested with DNase I (350 U) for 30 min at 37 1C. After DNase I digestion, 10 mg proteinase K (Promega, Madison, WI, USA) was added to all samples and incubated for 1 h at 50 1C. This was followed by 20 min incubation at 95 1C to inactivate the proteinase K. The digested sample was then applied to SYBR Green PCR system. A PE-Applied Biosystems Prism 7500 Sequence Detector (Foster City, CA, USA) was used for quantitative PCR. Concurrently, a DNA plasmid standard curve was set up in duplicate using 10 2 -10 6 AAV genome equivalents. Because the AAV genome is single stranded, to derive calculated DNaseresistant particle values, the initial template value was multiplied by the dilution factor (10 4 ), and then by 400 to derive a titer per milliliter (2.5 mlÂ400¼1 ml).
Transient transfection
Transfections were carried out using the TransFast Transfection Reagent (Promega) in 293T cells in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Transfection efficiency was normalized using a co-transfected luciferase reporter, pGL3 control (Promega). 293T cells (2.5Â10 5 ) were transfected with mixtures containing 2 mg GLP-1 plasmids and 0.2 mg pGL3 control. Concentrations of secreted GLP-1 were measured using an RIA (Linco) specific for the C terminus of GLP-1 or active GLP-1 ELISA kit (Linco). Luciferase activity was determined using luciferase assay kit (Promega).
Immunocytochemistry
For immunocytochemistry, 293T cells were seeded on a Lab-Tek chamber slide (Nunc, Rochester, NY, USA) and transfected the next day with dsAAV GLP-1 vector plasmid using Transfest transfection reagent (Promega) as per the manufacturer's protocols. Cells were fixed with 4% (v/v) paraformaldehyde in phosphate-buffered saline for 20 min at room temperature and washed three times. Samples were permeabilized by incubating the cells in 0.1% Triton X-100 in phosphate-buffered saline for 15 min at room temperature and then blocked by 5% bovine serum albumin in phosphate-buffered saline for 1 h at room temperature. Slides were incubated overnight with polyclonal rabbit anti-GLP-1 (Linco), washed and incubated with the FITC-conjugated goat anti-rabbit IgG for 1 h.
Immunoprecipitation and western blotting
At 48 h after transfection, 1 ml of cell culture medium was collected and centrifuged for 5 min at 2000 g, and precleared with 30 ml of GammaBind plus sepharose (GE Healthcare). Secreted GLP-1 was then immunoprecipitated using anti-GLP-1 antibody (Abcam, Cambridge, UK) at 4 1C overnight. The complex materials were separated on a 4-20% gradient SDS-polyacrylamide gel and transferred onto a polyvinylidene difluoride membrane, followed by western blot analysis.
Detection of cAMP upregulation
For bioassay of GLP-1 activity, we used an INS-1E cell line that expresses the GLP-1 receptor. The cells were grown in monolayer culture in RPMI 1640 medium containing 11.1 mmol l À1 glucose. The culture medium was supplemented with 10% heat-inactivated fetal calf serum, 1 mmol l À1 sodium pyruvate, 10 mmol l À1 HEPES, 2 mmol l À1 glutamine, 50 mmol l À1 b-mercaptoethanol, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The cells were cultured at 37 1C in a humidified 95% air, 5% CO 2 atmosphere. Cells were seeded in wells for 48 h before use in transient transfection experiment. The cells were transfected with the pCRE-Luc (Stratagene, La Jolla, CA, USA), inducible reporter plasmid in that the luciferase gene is driven by the cAMP response elements-containing promoter using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions and culture medium was replaced with fresh culture media after 4 h. The luciferase activity was analyzed 18 h later and was measured using a luciferase assay kit (Promega) and luminometer.
Insulin secretion assay
INS-1E cells were grown in monolayer culture in RPMI 1640 medium containing 11.1 mmol l À1 glucose. The culture medium was supplemented with 10% heat-inactivated fetal calf serum, 1 mmol l À1 sodium pyruvate, 10 mmol l À1 HEPES and 2 mmol l À1 glutamine, 50 mmol l À1 b-mercaptoethanol, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. The cells were cultured at 37 1C in a humidified 95% air, 5% CO 2 atmosphere. Cells were seeded in wells at a density of 3Â10 5 cells per culture well and grown to 60% confluence before use in dsAAV transduction. INS-1E cells were exposed to dsAAV GLP-1 or dsAAV GFP at 5Â10 3 v.g. per cell. Viral vector-transduced cells were further cultured for 6-7 days before using them for insulin release assay. On the day of experiment, cells were incubated in RPMI medium without glucose for 2 h. Cells were then washed two times with KRBH buffer (NaCl 140 mM, NaHCO 3 2 mM, KCl 3.6mM, NaH 2 PO 4 0.5 mM, MgSO 4 0.5 mM, HEPES 10 mM, CaCl 2 , 1.5 mM, bovine serum albumin 0.1%) and incubated for 30 min at 37 1C. Cells were then washed once with glucose-free KRBH and subsequently incubated for 60 min with KRBH containing 3 mM or 11.2 mM glucose. After 1 h of incubation, the collected supernatants were then immediately centrifuged to eliminate cells that might have detached from the well and contaminated the buffer. Supernatants were kept on ice used for insulin ELISA. The Insulin levels were measured using a rat/mouse insulin ELISA kit (Linco).
In vivo expression of GLP-1 in mice
To transfer liver, we directly injected 150 ml (total 1Â10 12 viral particles per mouse) of either dsAAV GFP or dsAAV GLP-1 into portal vein. Male db/db mice (C57BLKS/J-db/db, 7-or 8-week old, Japan SLC Inc., Hamamatsu, Shizuoka, Japan) were anesthetized with Zoletil (Virbac, Carros Cedex, France) and Rompun (Bayer HealthCare AG, Leverkusen, Germany). Following midline ventral laparotomy, a uniform volume of virus was delivered via a 1 cm 3 insulin syringe with a 31-gauge needle. All procedures were approved by the institutional animal care and use committee, and were performed in accordance with their guidelines. The fasting blood glucose levels were measured by using One Touch glucose meter (Allmedicus, Anyang, Gyeonggi-do, South Korea). For OGTT, mice were fasted for 15 h, a basal blood sample was collected from a tail vein (t¼0) for measurement of glucose using a blood glucose test meter (Allmedicus). The mice were gavaged with glucose (1.5 g kg À1 ) and additional blood samples were collected at t¼15, 30, 60, 90 and 120 min for glucose measurement.
GLP-1 levels in plasma form db/db mice were determined using GLP-1 RIA kit (Linco). Plasma insulin levels were determined by Rat/mouse Insulin ELISA kit (Linco).
RT-PCR analysis
Total RNA was extracted from liver and pancreas tissues using TRI reagent and gene expression was determined by RT-PCR. After cDNA synthesis, products were amplified using sequence-specific primers. The following paired primers were used: b-actin forward (F) 5¢-TGTTACCAACTGGGACGACA-3¢ and reverse (R) 5¢-TCTCAGCTGTGGTGGTGAAG-3¢ (392 bp); GLP-1 (F) 5¢-AGCGTGTTAGGCGACATG-3¢ and (R) 5¢-CTATCCTCGGCCTTTCACC-3¢ (114 bp); GFP (F) 5¢-GGCAAGCTGACCCTGAAGTT-3¢ and (R) 5¢-GGCGGA CTTGAAGAAGTCGT-3¢ (144 bp); Insulin I (F) 5¢-CTGCTGGCCCTGCTTGC-3¢ and (R) 5¢-GGGTCGAGGTGGGCCTT-3¢ (315 bp); Chop (F) 5¢-TATGAGGAT CTGCAGGAGGT-3¢ and (R) 5¢-TCAGCTAGCT GTGCCACTTT-3¢ (340 bp).
Quantification of islet area
Pancreatic sections (4 mm) were incubated overnight at 4 1C with guinea pig anti-insulin antibody (Dako Diagnostics, Mississauga, Ontario, Canada). The samples were then incubated for 1 h with biotinylated anti-guinea pig antibody (Vector Laboratories, Burlington, Ontario, Canada), and subsequently treated for 1 h with avidin-biotin complex (Vectastain Elite ABC Kit; Vector Laboratories). Sections were then stained with 3,3¢-diaminobenzidine tetrahydrochloride (DAB) for 10 min. After DAB staining, the sections were washed with tap water and counterstained with hematoxylin. Three sections of whole pancreas from each animal were scanned by dotslide virtual microscope following insulin immunohistochemistry. The relative islet area was determined by quantification of the cross-sectional area occupied by b-cells and the total pancreatic cross-sectional area with Metamorph (Universal Imaging, Downingtown, PA, USA) image analysis software. For the immunofluorescent labeling on paraffin sections, deparaffinized and antigen-retrieved slides were incubated for 1 h with anti-insulin guinea pig antibody and anti-glucagon rabbit antibody (Cell Signaling, Boston, MA, USA). After washing with phosphate-buffered saline, they were further incubated for 1 h in a mixture of biotinylated anti-guinea pig IgG antibody (Vector) followed by incubating in a Texas Red Avidin DCS (Vector). The sections were analyzed with a confocal scanning laser microscope (Carl Zeiss, Thornwood, NY, USA).
Statistical analysis
Data are expressed as mean ± s.d. The statistical comparisons among multiple groups were performed using analysis of variance followed by Fisher's post hoc protected least-significant difference test, and comparisons between two groups were performed using the unpaired t-test.
